Piramal Pharma Receives USFDA EIR for Sellersville Manufacturing Facility
Mumbai: Piramal Pharma Limited has announced that the US Food and Drug Administration (USFDA) has successfully concluded its inspection of the company's manufacturing facility located in Sellersville, USA, with the issuance of an Establishment Inspection Report (EIR), marking the formal closure of the regulatory inspection process.
The company disclosed the development through a regulatory filing. The filing pertains to the successful completion of the US FDA inspection at Piramal Pharma's Sellersville manufacturing facility in the United States.
In its filing, Piramal Pharma referred to its earlier communication dated May 10, 2026, through which it had informed the stock exchanges about the USFDA inspection being conducted at the Sellersville facility. The latest update confirms that, following the inspection, the USFDA has now issued the Establishment Inspection Report (EIR) for the site, indicating that the inspection has been successfully closed by the regulator.
The company informed the stock exchanges that the issuance of the EIR signifies the successful closure of the inspection by the US FDA. The disclosure was made for the information and records of the exchanges in compliance with applicable SEBI regulations governing listed entities.
